For instance, MYEOV upregulation is linked with undesirable survival outcome of pancreatic cancer (Tang et al., 2020a), which elevates the HES1 expression and triggers pancreatic cancer progression through enhancing SOX9 trans-activity (Liang et al., 2020). Here, HES1 is linked to familial pancreatic carcinoma.